Stada Arzneimittel AG's owners in private equity are delaying the scheduled initial public offering of the German pharmaceutical company until September due to recent market fluctuations. Originally planned to launch this week, Bain Capital and Cinven have decided to postpone the listing. The expected valuation of Stada was approximately €10 billion ($10.9 billion) with a target of raising about €1.5 billion in fresh capital. This move was anticipated to stimulate IPO activity in Europe. There were also preparations for a share sale by Oldenburgische Landesbank AG, backed by Apollo Global Management Inc. The company aims to reduce its debt by €3 billion from the current €5.6 billion level, as stated by CEO Peter Goldschmidt in an interview. Leading the IPO for Stada are JPMorgan Chase & Co., Morgan Stanley, Deutsche Bank AG, and Goldman Sachs Group Inc. Although details are subject to change, representatives for Bain, Cinven, and Stada have refrained from commenting. Stada focuses on selling generic drugs, consumer health products, and specialty medications for rare and chronic ailments.